Influenza, COVID-19, and RSV Vaccination Coverage Update

Carla Black, PhD
Immunization Services Division
National Center for Immunization and Respiratory Diseases

NAIIS

December 12, 2024

National Immunization Survey-Adult COVID Module (NIS-ACM) methods

- Random-digit-dial cellular telephone survey of adults age ≥18 years in the U.S.
- Respondents are sampled within all 50 states, District of Columbia, five local jurisdictions (Bexar County TX, Chicago IL, Houston TX, New York City NY, and Philadelphia County PA), Puerto Rico and the U.S. Virgin Islands.
- Data are weighted to represent the non-institutionalized U.S. population.
  - Estimates from the NIS-ACM may differ from estimates based on other data sources.
  - Subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status.
  - Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
- All responses are self-reported.
- Additional information available at: About the National Immunization Surveys

Vaccine Safety Datalink (VSD) methods

- **Used for in-season monitoring of vaccination coverage among pregnant persons**
- **Collaboration between CDC's Immunization Safety Office and 10 integrated health care organizations**
- **Vaccination status based on electronic healthcare records among people enrolled at participating VSD sites**
- **Influenza vaccination**
  - Denominator: persons with a pregnancy during the current influenza season (defined as August through March) beginning before or during the specified week.
  - Numerator: those who received a flu vaccine since July 1 of the respective flu season before or during pregnancy as of the specified week ending date

VSD methods (cont)

- **COVID-19 vaccination**
  - Denominator: persons with a pregnancy during the respective season* beginning before or during the specified week
  - Numerator: those who received a COVID-19 vaccine after the vaccine was available for the respective season before or during pregnancy as of the specified week ending date.
- **RSV vaccination**
  - Denominator: pregnant persons who reached at least 32 weeks' gestation since September 1, 2024
  - Numerator: those who have received an RSV vaccine during pregnancy as of the week ending date

* For the 2023–24 season the denominator included persons who were pregnant as of September 26, 2023. For the 2024–25 season the denominator includes persons who were pregnant as of September 5, 2024. These dates are approximately two weeks after COVID-19 vaccines were approved each season.

Influenza

Influenza vaccination coverage by age group, adults ≥18 years, Behavioral Risk Factor Surveillance System, United States, 2010–2024



Influenza vaccination coverage and intent among adults ≥18 years by end of November 2024 compared with 2023, NIS-ACM



- Coverage plus definite intent 11/30/2024: 49.6%
- Coverage plus definite intent 12/2/2023: 50.6%
- Final coverage 2023-24: 48.1%

Influenza Vaccination status and intent among adults ≥18 years, NIS-ACM

Key Takeaways/Changes/Summary of Data:

- Among adults aged ≥18 years responding to the National Immunization Survey through November 30, **38.6%** (95% CI: 37.5-39.8) reported having received an influenza vaccine since July 1, 2024.
- Among adults ≥65 years, **63.6%** (95% CI: 60.6-66.6) have received an influenza vaccine since July 1, 2024.

Weekly Influenza Vaccination Status and Intent Among Adults Age ≥18 Years, NIS-ACM (n = 169,106)



Probably or definitely will not get vaccinated
Probably will get vaccinated or unsure
Definitely will get vaccinated
Received influenza vaccine since 7/1/24

Influenza Vaccination Status and Intent Among Adults Age ≥18 Years by Demographics, NIS-ACM, November 24–30, 2024 (n = 9,403)





NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

Weekly cumulative estimated number of influenza vaccinations administered in retail pharmacies and physician medical offices among adults ≥18 years, 2023–24 and 2024–25 seasons, IQVIA



Influenza Vaccination Coverage Among Children 6 months–17 years, United States, 2010–2024



Data Source: National Immunization Survey-Flu (NIS-Flu)
Error bars represent 95% confidence intervals around the estimates.

Influenza vaccination coverage and parental intent among children 6 months–17 years by end of November 2024 compared with 2023, NIS-Flu



- Coverage plus definite intent 11/30/2024: 46.6%
- Coverage plus definite intent 12/2/2023: 55.9%
- Final coverage 2023-24: 53.8%

Influenza vaccination status and intent among children 6mo-17 years, NIS-Flu

Key Takeaways/Changes/Summary of Data:

- Based on interviews conducted October 1 – November 30, 2024,
  - 36.6% of children aged 6 months–17 years have received at least one dose of influenza vaccination since July 1, 2024.
  - 10.3% of children have a parent reporting they definitely will get their child vaccinated.
- There are sociodemographic differences in vaccination coverage and intent for vaccination.

Influenza Vaccination Status and Parental Intent Among Children Ages 6 Months–17 Years October 1–November 30, 2024 (n=23,741)



Unvaccinated, probably or definitely will not get vaccinated
Unvaccinated, probably will get vaccinated
Unvaccinated, definitely will get vaccinated
Received at least one influenza vaccine since 7/1/24

Influenza Vaccination Status and Parental Intent Among Children Ages 6 Months–17 Years by Demographics, November 24–November 30, 2024 (n=2,208)



Note: All estimates are enhanced estimates.

COVID-19

COVID-19 vaccination coverage and intent among adults ≥18 years, by end of November 2024 compared with 2023*, NIS-ACM



- Coverage plus definite intent 11/30/2024: 29.6%
- Coverage plus definite intent 12/2/2023: 31.0%
- Final coverage 2023-24: 22.9%

*2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 COVID-19 vaccines were first available at the end of August 2024.

COVID-19 vaccination coverage and intent among adults ≥65 years, by end of November 2024 compared with 2023*, NIS-ACM



- Coverage plus definite intent 11/30/2024: 52.2%
- Coverage plus definite intent 12/2/2023: 47.9%
- Final coverage 2023-24: 40.3%

*2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 COVID-19 vaccines were first available at the end of August 2024.

COVID-19 vaccination status and intent among adults ≥18 years, NIS-ACM

Key Takeaways/Changes/Summary of Data:

- Based on interviews through November 30, **20.0%** (95% CI: 19.2-20.8) of adults ages ≥18 years reported having received a 2024-25 COVID-19 vaccine.
- 9.6% (95% CI: 8.0-11.2) of adults said they definitely will get vaccinated, and 46.5% (95% CI: 43.9-49.1) said they probably or definitely will not get vaccinated.
- Among adults ≥65 years, **41.4%** (95% CI: 39.1-43.8) have received a 2024-25 COVID-19 vaccine since August 22, 2024.

Weekly COVID-19 Vaccination Status and Intent Among Adults Age ≥18 Years, NIS-ACM (n = 144,937)



Probably or definitely will not get vaccinated
Probably will get vaccinated or unsure
Definitely will get vaccinated
Received 2024-25 COVID-19 vaccine

COVID-19 Vaccination Status and Intent Among Adults Age ≥18 Years by Demographics, NIS-ACM, November 24–30, 2024 (n = 9,404)





NA: estimate not reported because denominator is <30; AI/AN: American Indian or Alaska Native; NH/OPI: Native Hawaiian or Other Pacific Islander.

COVID-19 vaccination coverage and parental intent among children 6 months–17 years by end of November 2024 compared with 2023, NIS-Flu



- Coverage plus definite intent 11/30/2024: 17.7%
- Coverage plus definite intent 12/2/2023: 28.2%
- Final coverage 2023-24: 14.9%

COVID-19 vaccination status and intent among children 6mo-17 years, NIS-Flu

Key Takeaways/Changes/Summary of Data:

- Based on interviews conducted October 1 – November 30, 2024,
  - 9.5% of children were up-to-date with 2024-25 COVID-19 vaccination, receiving the recommended number of doses since August 22, 2024.
  - 8.2% of children have a parent who said they definitely will get their child vaccinated,
  - 51.7% have a parent that said they probably or definitely will *not* get their child vaccinated.
- The percentage vaccinated was low for children across all sociodemographic groups.

COVID-19 Vaccination Status and Parental Intent Among Children Ages 6 Months–17 Years October 1–November 30, 2024 (n=24,957)



Unvaccinated, probably or definitely will not get vaccinated
Unvaccinated, probably will get vaccinated or unsure
Unvaccinated, definitely will get vaccinated
UTD with 2024-25 COVID-19 vaccine

COVID-19 Vaccination Status and Parental Intent Among Children Ages 6 Months–17 Years by Demographics, November 24–November 30, 2024 (n=2,359)



Note: All estimates are enhanced estimates.

RSV

Percentage of adults ≥75 years and 60–74 years with high-risk conditions ever vaccinated with RSV vaccine, 2024–25, NIS-ACM



Protection against RSV and intent for nirsevimab among infants <8 months, August – October 2024, NIS-ACM

Key Takeaways/Changes/Summary of Data:

- Among women aged 18-49 years with an infant born since April 2024 responding to the National Immunization Survey during September 29-October 26, 0.2% (95% CI: 0.0-0.5) reported the mother received RSV vaccination during pregnancy and their infant did not receive nirsevimab, 29.9% (95% CI: 20.8-39.1) reported their infant received nirsevimab, 33.6% (95% CI: 23.6-43.6) definitely will get nirsevimab for their infant, and 28.4% (95% CI: 18.2-38.5) probably will or were unsure if they will get nirsevimab for their infant.



Pregnant Women

Influenza vaccination coverage among pregnant women 18–49 years by season, Vaccine Safety Datalink



11/30/2024: 33.8%
12/2/2023: 34.5%

COVID-19 vaccination coverage among pregnant women 18–49 years, 2023–24 and 2024–25*, Vaccine Safety Datalink



*2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 COVID-19 vaccines were first available at the end of August 2024.

RSV vaccination coverage among pregnant women* 18–49 years, 2024–25 season, Vaccine Safety Datalink



*Among pregnant women who reached 32 weeks' gestation after September 1, 2024

Summary

- Coverage and intent for influenza vaccination among adults ≥18 years is similar so far this season compared with the same time last season
  - Coverage and intent among children is lower compared with last season
- COVID-19 vaccination coverage is higher among adults this season compared with last season, especially among adults ≥65 years
  - Among children, coverage remains low, and hesitancy has increased compared with last season
- RSV coverage ~43% among adults ≥75 years and ~32% among adults 60–74 years with high-risk conditions
- Influenza vaccination coverage among pregnant women similar to this time last season by remains lower than the 2019–20 season
- RSV vaccination coverage among pregnant women ~33% at the end of November 2024
- At the end of October 2024, ~30% of eligible infants were protected from RSV by nirsevimab or maternal RSV vaccination

Thank you!

cblack2@cdc.gov

For more information visit: RespVaxView | CDC

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov